Biohaven to present BHV-1530 cancer data
- Biohaven will present updated Phase 1 clinical data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026.
- The study is evaluating an FGFR3-directed antibody-drug conjugate in adults with advanced or metastatic solid tumors.
- Biohaven has started a combination cohort testing BHV-1530 with cemiplimab under a clinical supply agreement with Regeneron.
Biohaven (NYSE:BHVN) will present updated Phase 1 data for BHV-1530 at the EORTC-NCI-AACR oncology symposium in November 2026, covering the ongoing BHV1530-101 study.
The November 19 oral presentation in Barcelona will provide additional results from the trial evaluating BHV-1530, an FGFR3-directed antibody-drug conjugate, in adults with advanced or metastatic solid tumors.
Biohaven said previously disclosed data included confirmed partial responses in heavily pretreated patients, with no dose-limiting toxicities or FGFR inhibitor-class toxicities observed in the reported results.
Biohaven develops therapies across neurological, immunological, and oncology-related disease areas, including antibody-based drug candidates.
The company said it has started enrolling patients in a cohort evaluating BHV-1530 in combination with cemiplimab, with the study including dose escalation, expansion, and confirmation stages.
Frequently asked questions
More from United States
Oil prices extend gains as Middle East tensions rise
Magna posts higher Q3 earnings despite 4% sales decline
BP Q3 profit jumps to $8.46 billion as debt falls
Sanofi Q3 sales rise 16.2% to €14.44 billion
AstraZeneca revenue advances 7% in Q3 to $16.21 billion
First Northern profit climbs 11.1% to $16.8 million
